vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and SWK Holdings Corp (SWKH). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $8.7M, roughly 1.7× SWK Holdings Corp). On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -29.7%). SWK Holdings Corp produced more free cash flow last quarter ($26.8M vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -12.5%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
SWK Holdings Corp is a specialty finance firm focused on the healthcare and life sciences sectors. It provides tailored financing solutions including royalty monetization, structured debt, and asset-backed lending to biotech, pharmaceutical, medical device and diagnostic companies, with its core market centered in North America.
CSBR vs SWKH — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $8.7M |
| Net Profit | $268.0K | $-19.4M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | 9.9% |
| Net Margin | 1.8% | — |
| Revenue YoY | 11.5% | -29.7% |
| Net Profit YoY | -63.2% | -430.2% |
| EPS (diluted) | $0.02 | $-1.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $8.7M | ||
| Q3 25 | $14.0M | $10.9M | ||
| Q2 25 | $12.4M | $10.1M | ||
| Q1 25 | $17.0M | $11.8M | ||
| Q4 24 | $13.5M | $12.4M | ||
| Q3 24 | $14.1M | $10.4M | ||
| Q2 24 | $14.0M | $10.8M | ||
| Q1 24 | $12.0M | $11.4M |
| Q4 25 | $268.0K | $-19.4M | ||
| Q3 25 | $-436.0K | $8.8M | ||
| Q2 25 | $-1.8M | $3.5M | ||
| Q1 25 | $4.5M | $4.5M | ||
| Q4 24 | $728.0K | $5.9M | ||
| Q3 24 | $1.3M | $3.5M | ||
| Q2 24 | $-109.0K | $3.7M | ||
| Q1 24 | $-2.5M | $468.0K |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 9.9% | ||
| Q3 25 | -3.8% | 61.3% | ||
| Q2 25 | -16.2% | 46.1% | ||
| Q1 25 | 26.4% | 68.6% | ||
| Q4 24 | 5.4% | 44.7% | ||
| Q3 24 | 9.5% | 39.2% | ||
| Q2 24 | -1.9% | 8.3% | ||
| Q1 24 | -21.4% | 9.5% |
| Q4 25 | 1.8% | — | ||
| Q3 25 | -3.1% | 80.7% | ||
| Q2 25 | -14.9% | 35.2% | ||
| Q1 25 | 26.4% | 38.4% | ||
| Q4 24 | 5.4% | 47.5% | ||
| Q3 24 | 9.3% | 33.3% | ||
| Q2 24 | -0.8% | 33.9% | ||
| Q1 24 | -21.1% | 4.1% |
| Q4 25 | $0.02 | $-1.59 | ||
| Q3 25 | $-0.03 | $0.72 | ||
| Q2 25 | $-0.12 | $0.29 | ||
| Q1 25 | $0.31 | $0.37 | ||
| Q4 24 | $0.05 | $0.47 | ||
| Q3 24 | $0.09 | $0.28 | ||
| Q2 24 | $-0.01 | $0.30 | ||
| Q1 24 | $-0.19 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $42.8M |
| Total DebtLower is stronger | — | $33.0M |
| Stockholders' EquityBook value | $4.2M | $235.1M |
| Total Assets | $30.2M | $272.4M |
| Debt / EquityLower = less leverage | — | 0.14× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $42.8M | ||
| Q3 25 | $10.3M | $10.2M | ||
| Q2 25 | $9.8M | $8.0M | ||
| Q1 25 | $3.2M | $29.8M | ||
| Q4 24 | $2.8M | $5.9M | ||
| Q3 24 | $2.9M | $17.2M | ||
| Q2 24 | $2.6M | $5.5M | ||
| Q1 24 | $4.5M | $5.5M |
| Q4 25 | — | $33.0M | ||
| Q3 25 | — | $33.0M | ||
| Q2 25 | — | $33.0M | ||
| Q1 25 | — | $33.0M | ||
| Q4 24 | — | $33.0M | ||
| Q3 24 | — | $33.0M | ||
| Q2 24 | — | $33.0M | ||
| Q1 24 | — | $33.0M |
| Q4 25 | $4.2M | $235.1M | ||
| Q3 25 | $3.5M | $254.2M | ||
| Q2 25 | $3.8M | $246.5M | ||
| Q1 25 | $5.5M | $292.7M | ||
| Q4 24 | $681.0K | $288.7M | ||
| Q3 24 | $-332.0K | $283.4M | ||
| Q2 24 | $-1.9M | $282.8M | ||
| Q1 24 | $-2.1M | $279.9M |
| Q4 25 | $30.2M | $272.4M | ||
| Q3 25 | $30.5M | $289.4M | ||
| Q2 25 | $32.3M | $285.7M | ||
| Q1 25 | $30.6M | $331.3M | ||
| Q4 24 | $25.2M | $332.2M | ||
| Q3 24 | $24.9M | $321.3M | ||
| Q2 24 | $26.1M | $321.0M | ||
| Q1 24 | $26.8M | $322.0M |
| Q4 25 | — | 0.14× | ||
| Q3 25 | — | 0.13× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $27.3M |
| Free Cash FlowOCF − Capex | $-2.0M | $26.8M |
| FCF MarginFCF / Revenue | -13.1% | 308.1% |
| Capex IntensityCapex / Revenue | 1.6% | 5.9% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $43.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $27.3M | ||
| Q3 25 | $600.0K | $906.0K | ||
| Q2 25 | $6.9M | $7.8M | ||
| Q1 25 | $490.0K | $8.3M | ||
| Q4 24 | $-283.0K | $23.0M | ||
| Q3 24 | $311.0K | $6.3M | ||
| Q2 24 | $-1.8M | $5.4M | ||
| Q1 24 | $-919.0K | $4.4M |
| Q4 25 | $-2.0M | $26.8M | ||
| Q3 25 | $554.0K | $557.0K | ||
| Q2 25 | $6.6M | $7.7M | ||
| Q1 25 | $448.0K | $8.2M | ||
| Q4 24 | $-377.0K | $22.9M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | $-1.8M | $5.4M | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | 308.1% | ||
| Q3 25 | 4.0% | 5.1% | ||
| Q2 25 | 53.5% | 77.0% | ||
| Q1 25 | 2.6% | 69.1% | ||
| Q4 24 | -2.8% | 185.3% | ||
| Q3 24 | — | 60.4% | ||
| Q2 24 | -13.0% | 49.7% | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | 5.9% | ||
| Q3 25 | 0.3% | 3.2% | ||
| Q2 25 | 2.0% | 0.6% | ||
| Q1 25 | 0.2% | 0.8% | ||
| Q4 24 | 0.7% | 1.1% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.8% | 0.0% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | 0.11× | 1.82× | ||
| Q4 24 | -0.39× | 3.93× | ||
| Q3 24 | 0.24× | 1.82× | ||
| Q2 24 | — | 1.47× | ||
| Q1 24 | — | 9.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
SWKH
| Finance Receivables Segment | $8.4M | 96% |
| Other | $329.0K | 4% |
